mani
virus
encod
proteinas
essenti
infect
consequ
attract
chemotherapeut
target
biochemistri
structur
human
immunodefici
viru
proteinas
character
extens
potent
peptidemimet
inhibitor
develop
techniqu
strategi
use
improv
effici
compound
like
applic
viral
proteinas
mani
human
anim
virus
encod
proteinas
play
import
role
differ
stage
infect
cycl
includ
separ
function
differ
domain
precursor
polyprotein
enabl
cleavag
product
transport
differ
cellular
compart
regul
varieti
event
viral
replic
uncoat
activ
replic
enzym
morphogenesi
proteinas
essenti
viru
infect
therefor
come
seen
attract
target
chemotherapeut
intervent
particularli
unusu
cleavag
specif
differ
host
proteas
proteinas
encod
retrovirus
includ
hiv
human
tcell
leukemia
viru
identifi
grow
number
dna
positivesens
rna
virus
includ
adenovirus
herpesvirus
well
picornavirus
flavivirus
dengu
yellow
fever
virus
pestivirus
relat
hepat
c
viru
number
virus
caus
diseas
medic
veterinari
import
amen
convent
prevent
prophylact
measur
proteinas
inhibit
therefor
repres
valid
altern
therapeut
approach
mani
viral
proteinas
identifi
recent
character
consequ
earli
stage
illustr
potenti
strategi
analysi
viral
proteinas
design
develop
inhibitor
shall
therefor
focu
picornaviru
retroviru
proteinas
elicit
greatest
academ
industri
interest
result
character
detail
genet
organ
typic
retrovirus
gag
pol
gene
encod
inner
structur
replic
protein
respect
translat
polyprotein
cleav
eight
site
proteinas
pr
fig
tabl
polyprotein
transport
plasma
membran
cleavag
occur
bud
immatur
particl
result
morpholog
chang
associ
virion
matur
substrat
specif
pr
puzzl
pr
catalyz
specif
cleavag
small
number
polyprotein
site
show
appar
sequenc
conserv
analysi
viral
nonvir
substrat
suggest
subsit
absolut
specif
combin
moder
interact
may
suffici
confer
catalyt
specif
heterogen
composit
viral
polyprotein
cleavag
site
probabl
play
role
determin
rate
consequ
order
cleavag
differ
site
proteinasedefici
hiv
mutant
produc
noninfecti
immatur
virion
contain
unprocess
polyprotein
observ
crucial
consider
pr
therapeut
target
pr
c
symmetr
homodimer
aspartyl
proteinas
consist
two
ident
subunit
termini
interdigit
dimer
interfac
otherwis
topolog
pr
similar
pepsinlik
aspartyl
proteinas
techniqu
larg
scale
purif
recombin
pr
routin
assay
proteolyt
activ
fundament
prerequisit
develop
inhibitor
variou
method
report
success
design
substratebas
inhibitor
aspartyl
proteinas
pepsin
renin
suggest
strategi
design
analog
peptidemimet
inhibitor
pr
incorpor
nonhydrolyz
transitionst
mimic
substrat
analogu
approach
base
key
step
aspartyl
proteinas
catalysi
gener
tetrahedr
diol
hydrat
trigon
amid
fig
high
millimolar
k
valu
peptid
substrat
indic
potent
ie
nanomolar
pr
inhibitor
must
incorpor
structur
featur
significantli
increas
bind
affin
peptidebas
inhibitor
sever
disadvantag
includ
vulner
degrad
enzym
rapid
clearanc
poor
oral
absorpt
problem
commonli
address
minim
size
peptidelik
charact
promis
lead
compound
first
report
pr
inhibitor
pepstatin
diagnost
inhibitor
aspartyl
proteinas
weak
inhibitor
contain
two
statin
residu
embodi
transit
state
analogu
fig
identifi
potent
inhibitor
dreyer
et
al
compar
effect
pr
inhibitor
five
differ
class
dipeptid
isoster
insert
consensu
heptapeptid
templat
heptapeptid
shortest
substrat
cleav
effici
pr
statinebas
reduc
amid
ii
phosphin
iii
transit
state
analogu
exhibit
modest
potenc
placement
phegli
hydroxyethylen
dipeptid
isoster
iv
consensu
templat
yield
compound
inhibit
hiv
pr
nanomolar
concentr
vitro
prevent
polyprotein
process
virion
matur
viral
spread
cell
cultur
truncat
extens
structureact
analysi
pi
posit
led
identif
highli
potent
subnanomolar
pr
inhibitor
base
dihydroxyethylen
v
hydroxyethylen
iv
isoster
transit
state
analogu
potenc
enhanc
incorpor
residu
stabil
extend
inhibitor
structur
presum
due
optim
hydrogenbond
substrat
bind
cleft
exampl
residu
leuph
effect
replac
variou
substitut
aminobenzocycloalkan
pi
posit
accept
sidechain
unrel
natur
amino
acid
allow
modif
made
enhanc
solubl
thu
cell
penetr
substitut
may
reduc
bind
affin
k
enhanc
solubl
may
nevertheless
result
net
increas
antivir
activ
abil
cleav
amino
terminu
prolin
distinguish
hiv
pr
nonvir
aspartyl
proteinas
hydroxyethylamin
vi
structur
readili
accomod
prolyl
imino
acid
incorpor
number
potent
inhibitor
modif
protect
tripeptid
incorpor
structur
substitut
imino
residu
decahydroisoquinolin
pi
posit
yield
highli
potent
inhibitor
pr
vitro
cell
cultur
compound
ro
inhibitor
expect
consider
select
inde
inhibit
human
aspartyl
proteinas
gastricsin
renin
pepsin
less
concentr
typic
valu
ro
nm
cytotox
concentr
uninfect
host
cell
recent
report
indic
mg
oral
dose
everi
hour
suffici
maintain
mean
human
plasma
concentr
potenc
ro
strongli
depend
tight
bind
particularli
substitu
wherea
bind
second
class
hydroxyethylamin
inhibitor
contain
noncycl
secondari
amin
place
decahydroisoquinolin
residu
less
depend
interact
second
class
bind
tightli
pi
region
peptid
substrat
inher
asymmetr
pr
dimer
must
therefor
lose
perfect
c
symmetri
catalysi
symmetri
permiss
inhibitor
howev
might
even
improv
bind
affin
select
endogen
aspartyl
proteinas
consider
led
design
seriesof
diaminoalcoholand
diaminodiolbas
inhibitor
c
vii
pseudoc
symmetri
inhibitor
potent
even
subnanomolar
concentr
highli
select
vitro
suffer
poor
solubl
lead
modest
potenc
cell
cultur
strategi
circumv
defici
thu
enhanc
activ
cell
cultur
includ
modif
termin
residu
linkag
group
increas
solubl
interact
includ
extens
van
der
waal
contact
residu
defin
hydrophob
bind
pocket
hydrogen
bond
system
sandwich
inhibitor
strand
catalyt
cleft
flap
hydroxyl
group
type
v
vi
vii
inhibitor
form
hydrogen
bond
catalyt
aspart
significantli
complex
contain
tetrahedr
coordin
activesit
water
molecul
bridg
two
flap
residu
two
inhibitor
carbonyl
group
prompt
suggest
improv
inhibitor
would
contain
function
replac
water
similar
extend
conform
inhibitor
well
induc
conform
chang
caus
enzym
indic
possibl
model
improv
peptid
inhibitor
basi
known
structur
altern
approach
discov
novel
templat
design
nonpeptid
inhibitor
search
threedimension
structur
databas
molecul
shape
complementari
activesit
cleft
date
approach
led
identif
antipsychot
agent
haloperidol
weak
pr
inhibitor
picornavirida
famili
small
icosahedr
virus
includ
etiolog
agent
sever
import
human
anim
diseas
consist
five
genera
includ
rhinoviru
common
cold
viru
enteroviru
eg
polioviru
hepat
viru
picornavirus
positivesens
monopartit
rna
genom
encod
singl
larg
polyprotein
process
three
differ
proteolyt
activ
regard
serv
distinct
function
fig
tabl
initi
event
cascad
cleavag
amino
terminu
separ
p
structur
protein
precursor
nascent
polyprotein
secondli
function
protein
releas
nonstructur
protein
precursor
precursor
final
matur
cleavag
capsid
protein
occur
encapsid
viral
rna
yield
infecti
viru
particl
addit
role
viral
replic
proteinas
polioviru
implic
picornavirus
respons
aspect
dramat
inhibit
host
cell
rna
protein
synthesi
occur
infect
proteinas
involv
degrad
eukaryot
initi
factor
elffi
correl
shutoff
capdepend
translat
ro
inactiv
transcript
factor
iiic
inhibit
polymeras
iii
transcript
sequenc
align
inhibitor
studi
suggest
proteinas
relat
structur
trypsinlik
serin
proteinas
eight
site
within
polyprotein
fig
site
picornavirus
slightli
heterogen
polioviru
cleav
tyrgli
dipeptid
junction
within
threedimension
polymeras
although
correspond
site
picornavirus
gli
residu
pi
posit
variou
residu
occur
posit
aliphat
residu
occur
posit
site
mutagenesi
peptid
cleavag
experi
indic
cleavag
site
recognit
depend
minimum
substrat
length
six
residu
presenc
specif
residu
posit
differ
accord
viru
proteinas
addit
conform
determin
recognit
cleavag
site
within
polyprotein
larg
millimolar
k
valu
peptid
substrat
may
reflect
greater
conform
freedom
potenti
peptidemimet
hibitor
like
exhibit
similar
flexibl
must
therefor
conform
constrain
incorpor
structur
featur
increas
bind
affin
lack
absolut
specif
subsit
requir
peptid
substrat
extend
posit
indic
substrat
bind
cleft
probabl
capabl
extens
hydrogen
bond
interact
inhibitor
howev
inhibitor
ro
report
proteas
encod
sever
dna
virus
numer
rna
virus
addit
picornavirus
retrovims
discuss
although
potenti
target
chemotherapeut
intervent
signific
progress
inhibitor
develop
report
pr
year
sinc
identif
structur
pr
numer
inhibitor
complex
determin
highli
potent
peptidemimet
inhibitor
develop
knowledg
strategi
use
enhanc
potenc
specif
pr
inhibitor
overcom
inher
limit
peptidebas
inhibitor
like
prove
invalu
develop
peptidemimet
inhibitor
viral
proteinas
heinrikson
rl
complex
aid
assess
hiv
proteas
therapeut
target
chem
today
account
recent
progress
substratebas
inhibitor
design
complement
concis
summari
structur
hiv
pr
clear
exposit
applic
structurebas
inhibitor
design
norbeck
first
seri
disclosur
group
merck
illustr
strategi
select
modifi
termini
sidechain
residu
increas
potenc
reduc
size
peptid
charact
increas
solubl
henc
antivir
activ
hydroxyethylen
isosterebas
inhibitor
paper
describ
effect
modif
pi
residu
